GlassScriptPhysician profile
Angela N Trimble
NPI 1568066546
$1,701.94
in general payments reported to CMS, 2019-2025
19 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $271 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.49 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.58 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $143.92 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $132.43 | 2025 | |
| Collegium Pharmaceutical, INC. | $119.94 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $108.12 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Novo Nordisk INC | $90.25 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $76.82 | 2024-2025 | Farxiga, Breztri |
| Aimmune Therapeutics, INC. | $75.98 | 2025 | Zenpep |
| Neurocrine Biosciences, INC. | $71.41 | 2024-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $54.56 | 2025 | |
| Lilly USA, LLC | $53.00 | 2025 | Jardiance, Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $45.37 | 2025 | Cobenfy |
| Lundbeck LLC | $44.92 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $41.46 | 2024-2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $34.42 | 2025 | Uzedy |
| Phathom Pharmaceuticals, INC. | $23.64 | 2025 | Voquezna |
| Abbott Laboratories | $23.61 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $14.02 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Trimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.